136
Participants
Start Date
September 13, 2021
Primary Completion Date
March 30, 2026
Study Completion Date
March 30, 2026
vilastobart (XTX101)
vilastobart (XTX101) monotherapy
Atezolizumab
1200 mg administered every 3 weeks in combination with vilastobart (XTX101)
vilastobart (XTX101)
In combination with Atezolizumab
RECRUITING
University of Pittsburgh Medical Center- Hillman Cancer Center, Pittsburgh
RECRUITING
NEXT Virginia, Fairfax
RECRUITING
Duke University Medical Center, Durham
COMPLETED
Carolina BioOncology Institute, Huntersville
RECRUITING
Mayo Clinic Hospital, Jacksonville
RECRUITING
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
RECRUITING
Mayo Clinic Hospital, Rochester
COMPLETED
Mary Crowley Cancer Research, Dallas
RECRUITING
Tranquil Clinical Research, Webster
RECRUITING
Next Oncology, Austin
RECRUITING
Mayo Clinic Hospital, Phoenix
RECRUITING
USC/Norris Comprehensive Cancer Center, Los Angeles
RECRUITING
UCLA Hematology/Oncology- Santa Monica, Santa Monica
RECRUITING
City of Hope, Duarte
RECRUITING
City of Hope-Upland, Upland
RECRUITING
California Cancer Associates for Research and Excellence, cCARE, Encinitas
RECRUITING
California Cancer Associates for Research and Excellence, cCARE, San Marcos
RECRUITING
City of Hope-Lennar, Irvine
RECRUITING
Massachusetts General Hospital, Boston
Hoffmann-La Roche
INDUSTRY
Xilio Development, Inc.
INDUSTRY